NT5E and neoplasm: In the recently presented ARC-9 study (NCT04660812), a combination of AB928 with anti-PD-1 (zimberelimab), FOLFOX, and bevacizumab resulted in better PFS and OS compared to the regorafenib control arm in third-line, chemo-resistant mCRC (with baseline CD73 expression>1% in tumor cells).